Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Xofigo Patient Case Studies

Bayer has collaborated with healthcare professionals across the multidisciplinary team to develop a series of patient case studies. These case studies were developed as a promotional educational resource and share real-world experience from experts on the treatment and management of their patients with metastatic castration-resistant prostate cancer (mCRPC). Each case study covers the whole patient journey, from initial diagnosis and treatment decisions to outcomes and tolerability.


These case studies share a range of different patient profiles including different ages, treatment histories, concomitant medications and outcomes to help visualise and identify eligible mCRPC patients who may be suitable for treatment with Xofigo.


Xofigo Patient Case Study: A Nuclear Medicine perspective

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

By Dr Francis Sundram, Consultant Clinical Lead, Department of Nuclear Medicine, Unversity Hospital Southampton NHS Foundation Trust, Southampton


Patient: 62 years old when diagnosed with advanced prostate cancer who was chemo-ineligible due to his cardiac history.


Treatment goal: Prolong survival, reduce or improve the symptoms of bone-metastases, slow down the decline of quality of life during on-treatment period and to prolong time to skeletal-related events vs placebo.1 2nd line treatment with Xofigo


Xofigo monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment.1

This patient case study is initiated and funded by Bayer plc. No patient identifiable data or photos of patients are shared within these case studies and the appropriate consent from the patients was collected by the HCP prior to development. Individual responses and experiences to medicinal products may vary.


Dr Francis Sundram

Dr Francis Sundram

Dr Francis Sundram is a Nuclear Medicine Consultant at University Hospital Southampton NHS Foundation Trust, Southampton, UK. He has been Lead Clinician for PET-CT since 2008 and Clinical Lead for Nuclear Medicine since 2012. He leads the Wessex Peptide Receptor Radionuclide Therapy service and the Southampton radium therapy service, which was designated as one of ten UK reference centres and a leading European centre in 2016. He introduced selective internal radiation therapy (SIRT) in 2009, with Southampton being one of ten SIRT centres in England. He has authored/co-authored 17 publications in peer-reviewed journals and scientific magazines and 65 scientifically refereed abstract publications. Dr Sundram is also a BNMS Council Member and Trustee, acting as the Southeast/Wessex region BNMS representative and a BNMS Scientific Committee Member. He is also Royal College of Physicians Nuclear Medicine Regional Speciality Advisor.

Click below to view other Xofigo Patient Case Studies:

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.


Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email:


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.